In 2010, the hospital was among the first in the country to conduct trials for the drug bapineuzumab, which wasn’t approved but was a precursor to the drugs that were. Now, researchers are ...

Other candidates – including Pfizer and J&J's amyloid-targeting antibody bapineuzumab have crashed out of development in the last few years. Lilly's solanezumab is in the same class as Pfizer ...